company background image
1NE logo

Verrica Pharmaceuticals DB:1NE Stock Report

Last Price

€4.58

Market Cap

€196.7m

7D

2.7%

1Y

-24.3%

Updated

24 Mar, 2024

Data

Company Financials +

Verrica Pharmaceuticals Inc.

DB:1NE Stock Report

Market Cap: €196.7m

1NE Stock Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.

1NE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Verrica Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Verrica Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.58
52 Week HighUS$6.60
52 Week LowUS$2.60
Beta1.87
1 Month Change-6.15%
3 Month Change-18.21%
1 Year Change-24.30%
3 Year Change-59.82%
5 Year Change-53.55%
Change since IPO-73.15%

Recent News & Updates

Recent updates

Shareholder Returns

1NEDE PharmaceuticalsDE Market
7D2.7%2.6%1.4%
1Y-24.3%-24.2%7.5%

Return vs Industry: 1NE matched the German Pharmaceuticals industry which returned -24.2% over the past year.

Return vs Market: 1NE underperformed the German Market which returned 7.5% over the past year.

Price Volatility

Is 1NE's price volatile compared to industry and market?
1NE volatility
1NE Average Weekly Movement10.3%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1NE's share price has been volatile over the past 3 months.

Volatility Over Time: 1NE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2013100Ted Whitehttps://www.verrica.com

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.

Verrica Pharmaceuticals Inc. Fundamentals Summary

How do Verrica Pharmaceuticals's earnings and revenue compare to its market cap?
1NE fundamental statistics
Market cap€196.66m
Earnings (TTM)-€62.00m
Revenue (TTM)€4.74m

41.5x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1NE income statement (TTM)
RevenueUS$5.12m
Cost of RevenueUS$18.46m
Gross Profit-US$13.34m
Other ExpensesUS$53.66m
Earnings-US$66.99m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin-260.28%
Net Profit Margin-1,307.47%
Debt/Equity Ratio216.9%

How did 1NE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.